Curated News
By: NewsRamp Editorial Staff
May 13, 2026
SS Innovations Q1 Revenue Soars 117% on SSi Mantra Growth
TLDR
- SS Innovations' 117% revenue growth and expanding global footprint offer a competitive edge in affordable robotic surgery.
- Revenue rose 116.8% to $11.1M with 26 SSi Mantra installations and gross margin expanding to 48%.
- SS Innovations makes robotic surgery affordable and accessible globally, improving healthcare in underserved regions.
- The SSi Mantra system performed 9,744 surgeries across 11 countries, including 157 telesurgeries and 161 pediatric procedures.
Impact - Why it Matters
This news matters because SS Innovations is democratizing access to advanced robotic surgery, making it affordable and accessible globally. With a 117% revenue surge and expanding global footprint, the company's SSi Mantra system is poised to transform surgical care in underserved regions. For investors, the strong financial performance and zero debt signal robust growth potential. For healthcare providers and patients, the SSi Mantra's telesurgery capabilities and regulatory approvals in multiple countries mean more people can receive high-quality, minimally invasive surgery regardless of location.
Summary
SS Innovations International, Inc. (Nasdaq: SSII), a developer of innovative surgical robotic technologies, today announced record first quarter 2026 financial results, with revenue surging 116.8% to $11.1 million compared to $5.1 million in Q1 2025. The strong performance was driven by robust growth in installations of the SSi Mantra surgical robotic system, which reached 26 in the quarter, up 73.3% from 15 in the prior year period. Gross margin expanded to 48.0% from 21.2%, and gross profit rose 390.0% to $5.3 million. Net loss narrowed to $3.6 million, or $(0.02) per diluted share, from a net loss of $5.7 million, or $(0.03) per diluted share, in the first quarter of 2025. The company ended the quarter with $16.0 million in cash and equivalents, zero long-term debt, and a cumulative installed base of 194 SSi Mantra systems across eleven countries, with total surgeries reaching 9,744, including 157 telesurgeries, 482 cardiac procedures, and 161 pediatric surgeries.
Dr. Sudhir Srivastava, Chairman and CEO, attributed the record revenue to strong adoption by hospitals and physicians, highlighting the SSi Mantra's cutting-edge technology, user friendliness, and cost efficiency. Key developments in the quarter included regulatory approvals for the SSi Mantra in Sri Lanka and Kenya, and for telesurgery in Indonesia and the Philippines. The company also completed a private placement in March 2026, raising approximately $18.6 million in gross proceeds to fuel growth initiatives. Looking ahead, Dr. Srivastava outlined plans to strengthen the company's position in the Indian market, expand globally into underserved countries, and secure entry into the U.S. and European Union markets. The company expects the U.S. Food and Drug Administration to complete its review of the SSi Mantra's 510(k) premarket notification in 2026, and is also pursuing CE marking certification in the EU.
The SSi Mantra is a user-friendly, modular, multi-arm system with advanced features including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and telesurgery capability via the optional SSi MantrAsana Tele Surgeon Console. It supports over 40 different types of robotic endo-surgical instruments and has been clinically validated in India in more than 170 different types of surgical procedures. The company's newsroom offers the latest updates on SS Innovations, and the press release was distributed via PRISM MediaWire, a trusted press release distribution service.
Source Statement
This curated news summary relied on content disributed by PRISM Mediawire. Read the original source here, SS Innovations Q1 Revenue Soars 117% on SSi Mantra Growth
